About Cytoplasmic protein NCK2
Cytoplasmic protein NCK2 (NCK2) is a protein
from Homo sapiens identified by UniProt accession
O43639, 380 residues long.
MolForge cross-references it against 0 known binders and
76 disease associations.
Target properties
| Protein name | Cytoplasmic protein NCK2 |
|---|
| UniProt accession | O43639 |
|---|
| Gene | NCK2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 380 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (76)
Diseases linked to this target (Open Targets).
- mean platelet volume · score 0.46
- eosinophil count · score 0.45
- platelet component distribution width · score 0.40
- drug dependence · score 0.38
- eosinophil percentage of leukocytes · score 0.36
- amyloid-beta measurement · score 0.27
- monocyte count · score 0.26
- brain measurement · score 0.26
- breast adenocarcinoma · score 0.26
- mood disorder · score 0.25
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O43639-F1 | alphafold | PREDICTED | 70.88 | — |
Amino-acid sequence (380 residues)
MTEEVIVIAK WDYTAQQDQE LDIKKNERLW LLDDSKTWWR VRNAANRTGY VPSNYVERKN SLKKGSLVKN LKDTLGLGKT RRKTSARDAS PTPSTDAEYP ANGSGADRIY DLNIPAFVKF AYVAEREDEL SLVKGSRVTV MEKCSDGWWR GSYNGQIGWF PSNYVLEEVD EAAAESPSFL SLRKGASLSN GQGSRVLHVV QTLYPFSSVT EEELNFEKGE TMEVIEKPEN DPEWWKCKNA RGQVGLVPKN YVVVLSDGPA LHPAHAPQIS YTGPSSSGRF AGREWYYGNV TRHQAECALN ERGVEGDFLI RDSESSPSDF SVSLKASGKN KHFKVQLVDN VYCIGQRRFH TMDELVEHYK KAPIFTSEHG EKLYLVRALQ
Explore Cytoplasmic protein NCK2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets